Close Menu

In PLoS One this week, MIT researchers say they've developed the first ever broad-spectrum antiviral therapeutic. Instead of taking a pathogen-specific approach to developing antivirals, the team has created a new approach, called Double-Stranded RNA Activated Caspase Oligomerizer, or DRACO, which selectively induces apoptosis in cells that contain viral dsRNA, and kills infected cells without harming normal cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.